HRP20100653T1 - Oralne smjese za apsorpciju fosfornih spojeva - Google Patents
Oralne smjese za apsorpciju fosfornih spojeva Download PDFInfo
- Publication number
- HRP20100653T1 HRP20100653T1 HR20100653T HRP20100653T HRP20100653T1 HR P20100653 T1 HRP20100653 T1 HR P20100653T1 HR 20100653 T HR20100653 T HR 20100653T HR P20100653 T HRP20100653 T HR P20100653T HR P20100653 T1 HRP20100653 T1 HR P20100653T1
- Authority
- HR
- Croatia
- Prior art keywords
- mixture
- binding
- substance
- pharmaceutically acceptable
- calcium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 23
- 150000003018 phosphorus compounds Chemical class 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000011574 phosphorus Substances 0.000 claims abstract 14
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract 14
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract 6
- 201000005991 hyperphosphatemia Diseases 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims 11
- -1 phosphorus compound Chemical class 0.000 claims 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- 229920001661 Chitosan Polymers 0.000 claims 3
- 239000007937 lozenge Substances 0.000 claims 3
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 2
- 229910017569 La2(CO3)3 Inorganic materials 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- 229940024545 aluminum hydroxide Drugs 0.000 claims 2
- 239000003957 anion exchange resin Substances 0.000 claims 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 2
- 235000011092 calcium acetate Nutrition 0.000 claims 2
- 239000001639 calcium acetate Substances 0.000 claims 2
- 229960005147 calcium acetate Drugs 0.000 claims 2
- 235000010410 calcium alginate Nutrition 0.000 claims 2
- 239000000648 calcium alginate Substances 0.000 claims 2
- 229960002681 calcium alginate Drugs 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 229960003563 calcium carbonate Drugs 0.000 claims 2
- 235000010216 calcium carbonate Nutrition 0.000 claims 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims 2
- 239000001354 calcium citrate Substances 0.000 claims 2
- 229960004256 calcium citrate Drugs 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 235000009508 confectionery Nutrition 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 150000002603 lanthanum Chemical class 0.000 claims 2
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 claims 2
- 229960001633 lanthanum carbonate Drugs 0.000 claims 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims 2
- 235000011285 magnesium acetate Nutrition 0.000 claims 2
- 239000011654 magnesium acetate Substances 0.000 claims 2
- 229940069446 magnesium acetate Drugs 0.000 claims 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 2
- 239000001095 magnesium carbonate Substances 0.000 claims 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 2
- 229960001708 magnesium carbonate Drugs 0.000 claims 2
- 235000014380 magnesium carbonate Nutrition 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229920000083 poly(allylamine) Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001055 chewing effect Effects 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oralna smjesa za kontinuirano sporo oslobadanje koja sadrzi tvar za vezanje fosfornog spoja i najmanje jedan farmaceutski prihvatljivi nosac i/ili ekscipijens, naznacena time sto je spomenuta tvar za vezanje fosfornog spoja izabrana iz skupine koja se sastoji od polimera za vezanje fosfata, farmaceutski prihvatljive soli lantana, farmaceutski prihvatljive soli magnezija, farmaceutski prihvatljive soli kalcija, farmaceutski prihvatljive anionske ionoizmjenjivacke smole i polisaharida za vezanje fosfornog spoja, za primjenu u lijecenju hiperfosfatemije tijekom perioda uzdrzavanja od hrane, pri cemu se smjesa drzi u ustima sve dok se ne potrosi tvar za vezanje fosfornog spoja. Patent sadrzi jos 14 patentnih zahtjeva.
Claims (15)
1. Oralna smjesa za kontinuirano sporo oslobađanje koja sadrži tvar za vezanje fosfornog spoja i najmanje jedan farmaceutski prihvatljivi nosač i/ili ekscipijens, naznačena time što je spomenuta tvar za vezanje fosfornog spoja izabrana iz skupine koja se sastoji od polimera za vezanje fosfata, farmaceutski prihvatljive soli lantana, farmaceutski prihvatljive soli magnezija, farmaceutski prihvatljive soli kalcija, farmaceutski prihvatljive anionske ionoizmjenjivačke smole i polisaharida za vezanje fosfornog spoja, za primjenu u liječenju hiperfosfatemije tijekom perioda uzdržavanja od hrane, pri čemu se smjesa drži u ustima sve dok se ne potroši tvar za vezanje fosfornog spoja.
2. Smjesa prema zahtjevu 1, naznačena time što je spomenuta smjesa dodatno kombinirana s najmanje još jednom pojedinačnom dozom spomenute tvari za vezanje fosfornog spoja koja se odmah guta, tako da se sastoji od dvije pojedinačne doze u najmanje jednom terapijskom obliku.
3. Smjesa prema zahtjevima 1 i 2, naznačena time što je spomenuta tvar za vezanje fosfora izabrana iz skupine koja se sastoji od polialilamin hidroklorida, polialilamin karbonata, lantan karbonata, aluminij hidroksida, magnezij acetata, magnezij karbonata, kalcij karbonata, kalcij acetata, kalcij citrata, kalcij alginata, stiren-divinilbenzolskih anionskih izmjenjivačkih smola i kitosana.
4. Smjesa prema zahtjevima 1-2, naznačena time što je spomenuta tvar za vezanje fosfora kitosan.
5. Smjesa prema zahtjevima 1-4, naznačena time što je spomenuta smjesa u obliku pilula, pastila, tableta, kapsula, praškastih smjesa, otopina, suspenzija, emulzija, slatkiša.
6. Smjesa prema zahtjevima 1-4, naznačena time što je spomenuta smjesa u obliku tableta za žvakanje, vrećica, sirupa, otopina za ispiranje usta, žvakaće gume, gumenih bombona, tableta za sisanje i bombona za sisanje.
7. Smjesa prema zahtjevima 1-6, naznačena time što se spomenuta smjesa primjenjuje za bolesti izabrane iz skupine koja se sastoji od bubrežnih bolesti, insuficijencije bubrega, hipoparatiroidizma, osteoporoze i ateroskleroze.
8. Smjesa prema zahtjevu 7, naznačena time što se spomenuta smjesa primjenjuje kod uremičnih pacijenata koji se podvrgavaju liječenju dijalizom.
9. Smjesa prema zahtjevu 7, naznačena time što se spomenuta smjesa primjenjuje kod pacijenata s kroničnom insuficijencijom bubrega pod konzervativnom terapijom.
10. Primjena tvari za vezanje fosfornog spoja, naznačena time što se spomenuta tvar za vezanje fosfornog spoja bira iz skupine koja se sastoji od polimera za vezanje fosfata, farmaceutski prihvatljive soli lantana, farmaceutski prihvatljive soli magnezija, farmaceutski prihvatljive soli kalcija, farmaceutski prihvatljive anionske ionoizmjenjivačke smole i polisaharida za vezanje fosfora, za dobivanje oralne smjese za kontinuirano sporo oslobađanje koja se treba držati u ustima sve dok se ne potroši tvar za vezanje fosfora za liječenje hiperfosfatemije tijekom perioda uzdržavanja od hrane.
11. Primjena prema zahtjevu 10, naznačena time što je spomenuta smjesa dodatno kombinirana s najmanje još jednom pojedinačnom dozom spomenute tvari za vezanje fosfornog spoja koja se odmah guta, tako da se sastoji od dvije pojedinačne doze u najmanje jednom terapijskom obliku
12. Primjena prema zahtjevima 10-11, naznačena time što se spomenuta tvar za vezanje fosfora bira iz skupine koja se sastoji od polialilamin hidroklorida, polialilamin karbonata, lantan karbonata, aluminij hidroksida, magnezij acetata, magnezij karbonata, kalcij karbonata, kalcij acetata, kalcij citrata, kalcij alginata, stiren-divinilbenzolskih anionskih izmjenjivačkih smola i kitosana.
13. Primjena prema zahtjevu 10-12, naznačena time što se spomenuta smjesa primjenjuje za bolest izabranu iz skupine koja se sastoji od bubrežnih bolesti, insuficijencije bubrega, hipoparatiroidizma, osteoporoze i ateroskleroze.
14. Primjena prema zahtjevu 13, naznačena time što se spomenuta smjesa primjenjuje kod uremičnih pacijenata koji se podvrgavaju liječenju dijalizom.
15. Primjena prema zahtjevu 13, naznačena time što se spomenuta smjesa primjenjuje kod pacijenata s kroničnom insuficijencijom bubrega pod konzervativnom terapijom
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000015A ITME20040015A1 (it) | 2004-12-07 | 2004-12-07 | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| PCT/EP2005/056289 WO2006061336A2 (en) | 2004-12-07 | 2005-11-29 | Oral compositions for absorption of phosphorus compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100653T1 true HRP20100653T1 (hr) | 2011-01-31 |
Family
ID=36035790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100653T HRP20100653T1 (hr) | 2004-12-07 | 2010-11-29 | Oralne smjese za apsorpciju fosfornih spojeva |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7815898B2 (hr) |
| EP (1) | EP1827386B1 (hr) |
| JP (1) | JP5049135B2 (hr) |
| KR (1) | KR101283820B1 (hr) |
| CN (1) | CN101068535A (hr) |
| AT (1) | ATE481091T1 (hr) |
| BR (1) | BRPI0518517A2 (hr) |
| CA (1) | CA2587924C (hr) |
| CY (1) | CY1110985T1 (hr) |
| DE (1) | DE602005023648D1 (hr) |
| DK (1) | DK1827386T3 (hr) |
| ES (1) | ES2352957T3 (hr) |
| HR (1) | HRP20100653T1 (hr) |
| IT (1) | ITME20040015A1 (hr) |
| MX (1) | MX2007006704A (hr) |
| PL (1) | PL1827386T3 (hr) |
| PT (1) | PT1827386E (hr) |
| RS (1) | RS51507B (hr) |
| RU (1) | RU2392926C2 (hr) |
| SI (1) | SI1827386T1 (hr) |
| WO (1) | WO2006061336A2 (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| ITRM20060204A1 (it) * | 2006-04-10 | 2007-10-11 | Vincenzo Savica | Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche |
| JP2009542653A (ja) * | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤 |
| US7943597B2 (en) | 2008-04-08 | 2011-05-17 | Cypress Pharmaceutical, Inc. | Phosphate-binding chitosan and uses thereof |
| AU2008354325A1 (en) * | 2008-04-08 | 2009-10-15 | Cypress Pharmaceutical, Inc. | Phosphate-binding chitosan and uses thereof |
| US8877907B2 (en) | 2010-06-07 | 2014-11-04 | The Johns Hopkins University | Molecularly imprinted polymers |
| US9314523B2 (en) | 2010-09-21 | 2016-04-19 | Elwha Llc | Ingestible salt grabber |
| EP2441436A1 (de) * | 2010-10-13 | 2012-04-18 | Fresenius Medical Care Deutschland GmbH | Phosphatbinderformulierung zur einfachen Einnahme |
| US9402808B2 (en) | 2011-01-19 | 2016-08-02 | Panacea Biotec Limited | Liquid oral composition of lanthanum salts |
| EP2699099A1 (en) * | 2011-04-20 | 2014-02-26 | Gumlink A/S | Chewing gum comprising chitosan for use in reduction of the level of free phosphorus compounds in the digestive juice |
| WO2012143008A1 (en) | 2011-04-20 | 2012-10-26 | Gumlink A/S | Reduction of the level of free phosphorus compounds in the digestive juice |
| ES2607986T3 (es) * | 2011-06-08 | 2017-04-05 | Kai Pharmaceuticals, Inc. | Agentes terapéuticos para regular el fósforo en suero |
| WO2014039477A1 (en) * | 2012-09-04 | 2014-03-13 | The Board Of Regents Of The University Of Texas System | Citrate-rich calcium-magnesium supplement and uses thereof |
| WO2014166545A1 (en) | 2013-04-12 | 2014-10-16 | Cm&D Pharma Ltd | Compositions comprising a mixture of elastomers and chitosan and use thereof for treating disorders of phosphorous mineral metabolism |
| EP3287133B1 (en) | 2013-06-05 | 2019-04-17 | Tricida Inc. | Proton-binding polymers for oral administration |
| EP2818176A1 (en) | 2013-06-27 | 2014-12-31 | Virbac | Composition for the treatment of progressive renal diseases |
| CN103536977A (zh) * | 2013-11-04 | 2014-01-29 | 于杰 | 血液灌流器 |
| US9744128B2 (en) | 2014-06-05 | 2017-08-29 | Mastix LLC | Method for manufacturing medicated chewing gum without cooling |
| JP6903576B2 (ja) | 2014-12-10 | 2021-07-14 | トリシダ・インコーポレイテッドＴｒｉｃｉｄａ， Ｉｎｃ． | 経口投与用プロトン結合ポリマー |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
| US11266684B2 (en) | 2017-11-03 | 2022-03-08 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| TW201940175A (zh) * | 2017-11-29 | 2019-10-16 | 世展科技股份有限公司 | 磷結合方法 |
| US11273123B2 (en) | 2018-07-18 | 2022-03-15 | USpharma Ltd | Chewable pharmaceutical dosage forms |
| CN109528764B (zh) * | 2018-09-30 | 2021-04-06 | 北京市中关村医院 | 一种凝胶基层状无机物磷结合剂及其制备方法和用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3818807A (en) * | 1972-12-06 | 1974-06-25 | Eng Concrete Placer Inc | Slurry pump piston seal |
| US4181718A (en) * | 1975-12-29 | 1980-01-01 | Mason Norbert S | Polyanion-stabilized aluminum hydrogels |
| US4163777A (en) | 1977-04-29 | 1979-08-07 | Lewis/Howe Company | Controlled antacid delivery form and method of treatment therewith |
| US4163177A (en) * | 1977-10-17 | 1979-07-31 | Ward Derrick A | Oscillation generator providing oscillations of varying amplitude |
| US4160820A (en) * | 1977-11-28 | 1979-07-10 | General Mills, Inc. | Plaque inhibiting composition and method |
| US4515769A (en) * | 1981-12-01 | 1985-05-07 | Borden, Inc. | Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same |
| US4386106A (en) * | 1981-12-01 | 1983-05-31 | Borden, Inc. | Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition |
| US4512968A (en) * | 1982-11-30 | 1985-04-23 | Lion Corporation | Oral compositions |
| EP0187703B1 (en) * | 1985-01-11 | 1992-08-05 | Teijin Limited | Sustained release preparation |
| JPS61161216A (ja) * | 1985-01-11 | 1986-07-21 | Teijin Ltd | キトサン類を用いた徐放性医薬品組成物 |
| JPS62132830A (ja) * | 1985-12-05 | 1987-06-16 | Teijin Ltd | 徐放性医薬品組成物 |
| JPS63310833A (ja) * | 1987-06-10 | 1988-12-19 | Nippon Medical Supply Corp | リン吸着カプセル |
| DE3936319C3 (de) * | 1989-11-01 | 1997-05-07 | Bartz Volker | Phosphatbinder zur oralen Verabreichung |
| US5030459A (en) * | 1989-11-07 | 1991-07-09 | Warner-Lambert Company | High impact mint flavor for high base chewing gum |
| JP2884124B2 (ja) * | 1992-01-31 | 1999-04-19 | 鈴与株式会社 | リン吸着剤 |
| US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| GB9506126D0 (en) * | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
| ES2162658T3 (es) * | 1996-03-05 | 2002-01-01 | Mitsubishi Chem Corp | Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia. |
| IE980990A1 (en) * | 1998-11-27 | 2000-05-31 | Fuisz Internat Ltd | Composition and Method for Medicated Chewing Gum Delivery System |
| DE19917705C1 (de) | 1999-04-20 | 2000-12-28 | Vitasyn Gmbh | Mittel zur Therapie von Hyperphosphatämie |
| US6645535B2 (en) * | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
| FI121528B (fi) * | 2000-10-30 | 2010-12-31 | Biohit Oyj | Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa |
| US20030072841A1 (en) * | 2001-03-19 | 2003-04-17 | The Procter & Gamble Campany | Polybutene containing chewing gum and confection |
| ITMI20012320A1 (it) * | 2001-11-06 | 2003-05-06 | Perfetti Van Melle Spa | Composizioni orali solide anti-tartaro e anti-placca batterica, utilicome coadiuvanti nell'igiene odonto-stomatologica |
| IL162823A0 (en) * | 2002-01-03 | 2005-11-20 | Yissum Res Dev Co | Edible compositions capable of removing oral biofilm |
| US7244455B2 (en) * | 2002-01-16 | 2007-07-17 | Warner-Lambert Company | Center-filled chewing gum containing a deliverable form of calcium |
| SE0302947D0 (sv) * | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
| EP2792363B1 (en) * | 2003-08-26 | 2016-06-29 | Shire Biopharmaceuticals Holdings Ireland Limited | Pharmaceutical formulation comprising lanthanum compounds |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| US8323683B2 (en) * | 2005-05-18 | 2012-12-04 | Mcneil-Ppc, Inc. | Flavoring of drug-containing chewing gums |
| US20070207206A1 (en) * | 2006-03-02 | 2007-09-06 | Rice Bronwyn C | Chewable pain formula |
-
2004
- 2004-12-07 IT IT000015A patent/ITME20040015A1/it unknown
-
2005
- 2005-11-29 PT PT05810997T patent/PT1827386E/pt unknown
- 2005-11-29 PL PL05810997T patent/PL1827386T3/pl unknown
- 2005-11-29 ES ES05810997T patent/ES2352957T3/es active Active
- 2005-11-29 US US11/792,047 patent/US7815898B2/en not_active Expired - Fee Related
- 2005-11-29 RU RU2007125702/15A patent/RU2392926C2/ru not_active IP Right Cessation
- 2005-11-29 MX MX2007006704A patent/MX2007006704A/es active IP Right Grant
- 2005-11-29 DE DE602005023648T patent/DE602005023648D1/de active Active
- 2005-11-29 EP EP05810997A patent/EP1827386B1/en active Active
- 2005-11-29 JP JP2007544881A patent/JP5049135B2/ja not_active Expired - Fee Related
- 2005-11-29 KR KR1020077012746A patent/KR101283820B1/ko not_active IP Right Cessation
- 2005-11-29 WO PCT/EP2005/056289 patent/WO2006061336A2/en active Application Filing
- 2005-11-29 BR BRPI0518517-3A patent/BRPI0518517A2/pt not_active IP Right Cessation
- 2005-11-29 CN CNA2005800414580A patent/CN101068535A/zh active Pending
- 2005-11-29 AT AT05810997T patent/ATE481091T1/de active
- 2005-11-29 DK DK05810997.6T patent/DK1827386T3/da active
- 2005-11-29 RS RSP-2010/0513A patent/RS51507B/en unknown
- 2005-11-29 CA CA2587924A patent/CA2587924C/en not_active Expired - Fee Related
- 2005-11-29 SI SI200531182T patent/SI1827386T1/sl unknown
-
2010
- 2010-08-23 US US12/861,539 patent/US20100316578A1/en not_active Abandoned
- 2010-09-16 US US12/883,498 patent/US8518379B2/en not_active Expired - Fee Related
- 2010-11-29 HR HR20100653T patent/HRP20100653T1/hr unknown
- 2010-12-10 CY CY20101101144T patent/CY1110985T1/el unknown
-
2014
- 2014-08-18 US US14/462,038 patent/US20140356297A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0518517A2 (pt) | 2008-11-25 |
| RS51507B (en) | 2011-06-30 |
| ITME20040015A1 (it) | 2005-03-07 |
| CN101068535A (zh) | 2007-11-07 |
| US20100316578A1 (en) | 2010-12-16 |
| WO2006061336A2 (en) | 2006-06-15 |
| ES2352957T3 (es) | 2011-02-24 |
| WO2006061336A3 (en) | 2006-09-14 |
| US20080125394A1 (en) | 2008-05-29 |
| EP1827386B1 (en) | 2010-09-15 |
| PT1827386E (pt) | 2010-12-03 |
| ATE481091T1 (de) | 2010-10-15 |
| CA2587924C (en) | 2013-08-20 |
| US20110002858A1 (en) | 2011-01-06 |
| SI1827386T1 (sl) | 2011-01-31 |
| US20140356297A1 (en) | 2014-12-04 |
| US7815898B2 (en) | 2010-10-19 |
| CY1110985T1 (el) | 2015-06-11 |
| RU2392926C2 (ru) | 2010-06-27 |
| PL1827386T3 (pl) | 2011-05-31 |
| DK1827386T3 (da) | 2011-07-11 |
| EP1827386A2 (en) | 2007-09-05 |
| KR20070090904A (ko) | 2007-09-06 |
| JP2008523022A (ja) | 2008-07-03 |
| MX2007006704A (es) | 2008-01-16 |
| RU2007125702A (ru) | 2009-01-20 |
| KR101283820B1 (ko) | 2013-07-15 |
| DE602005023648D1 (de) | 2010-10-28 |
| US8518379B2 (en) | 2013-08-27 |
| CA2587924A1 (en) | 2006-06-15 |
| JP5049135B2 (ja) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100653T1 (hr) | Oralne smjese za apsorpciju fosfornih spojeva | |
| ES2787220T3 (es) | Cápsulas blandas llenas de líquido | |
| TWI446906B (zh) | 以γ－羥基丁酸為基礎的新穎組成物 | |
| AU2011316103B2 (en) | Phosphate binder formulation for simple ingestion | |
| JP2002539245A5 (hr) | ||
| CZ156598A3 (cs) | Použití flurbiprofenu k přípravě léčiva k léčení bolesti v krku | |
| KR20090094076A (ko) | 아세트아미노펜／이부프로펜 병용물 | |
| AU607153B2 (en) | Oral sustained release composition of sodium monofluorophasphate and a calcium containing composition | |
| US20220008331A1 (en) | Pharmaceutical compositions comprising flurbiprofen | |
| US20170157001A1 (en) | Compositions Comprising Strontium and Uses Thereof in the Treatment or Prevention of Gingivitis, Periodontitis, Periodontitis as a Manifestation of Systemic Diseases, and Necrotizing Periodontal Diseases | |
| SK284728B6 (sk) | Farmaceutický prostriedok obsahujúci ibuprofen a domperidone na ošetrovanie migrény | |
| JP6832195B2 (ja) | 経口液剤及び経口固形剤 | |
| ES2952013T3 (es) | Combinación de ibuprofeno y tramadol para aliviar el dolor | |
| AU4307396A (en) | Kit for osteoporosis treatment cycle | |
| AU2019405489A1 (en) | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder | |
| CN102138893A (zh) | 制备赖氨洛芬氯化钠注射液的工艺方法及其用途 | |
| TR201511854A1 (tr) | Oral terapöti̇k formülasyonlar |